Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.

Date
2022
Author
Rodriguez-Vida, Alejo
Morales-Barrera, Rafael
Powles, Thomas
Ozguroglu, Mustafa
Csoszi, Tibor
Loriot, Yohann
Flechon, Aude
Matsubara, Nobuaki
Geczi, Lajos
Cheng, Susanna Y.
Fradet, Yves
Oudard, Stephane
Gunduz, Seyda
Ma, Junshui
Rajasagi, Mohini
Vajdi, Amir
Cristescu, Razvan
Imai, Kentaro
Moreno, Blanca Homet
Alva, Ajjai Shivaram
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/183478
https://doi.org/10.1200/jco.2022.40.6_suppl.540
Collections